NASDAQ · VALN
Valneva SE
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for VALN: Nov 19, 2026
Valneva SE American Depositary Shares is estimated to report earnings on 11/19/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.23. The reported EPS for the same quarter last year was $-0.61.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.23 | $-0.18 | $-0.28 | 2 |
| Dec 2026 | $-0.16 | $-0.05 | $-0.26 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · The Motley Fool · MarketBeat · Zacks- RTTNews · Oct 8, 2:47 AM EDTUK Revokes Marketing Authorisation For Valneva's Chikungunya Vaccine IXCHIQ; Shares Slide(RTTNews) – Valneva SE (VALN), a speciality vaccine company, announced that after a further benefit-risk assessment of IXCHIQ for travellers by the United Kingdom's (UK) Commission on Human Medicines (CHM), the Medicines and Healthcare products Regulatory Agency (MHRA) revoked th
- The Motley Fool · Sep 8, 4:54 PM EDTWhy Pfizer Stock Was so Healthy in AugustIt also advanced a pair of promising developmental drugs.
- The Motley Fool · Aug 20, 3:44 PM EDTValneva (VALN) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · Aug 14, 6:44 AM EDTPfizer And Valneva's Lyme Vaccine Clears EMA Review Gate(RTTNews) – Pfizer Inc. (PFE) and Valneva SE's (VALN) Lyme disease vaccine candidate has reached a key regulatory milestone, with the European Medicines Agency (EMA) validating the companies' Marketing Authorization Application (MAA) for PF-07307405, a 6-valent OspA-based vaccine
- RTTNews · Aug 14, 3:26 AM EDTPfizer, Valneva's Lyme Disease Vaccine Application Validated By EMA(RTTNews) – Pfizer Inc. (PFE) and Valneva SE (VALN) said Friday that the European Medicines Agency (EMA) has validated their Marketing Authorization Application for PF-07307405, a Lyme disease vaccine candidate, allowing the regulator to begin its assessment.
- MarketBeat · Aug 13, 3:04 PM EDTValneva Q2 Earnings Call HighlightsNovavax’s dispute resolution and upcoming earnings callValneva (NASDAQ:VALN) reported lower first-half revenue and wider losses for 2026, while maintaining its full-year sales outlook and emphasizing its cash position, restructuring measures and expectations for regulatory progre
- MarketBeat · May 13, 3:10 PM EDTValneva Q1 Earnings Call HighlightsNovavax’s dispute resolution and upcoming earnings callValneva (NASDAQ:VALN) reported lower first-quarter revenue and a wider loss for 2026, while management said the company is focused on conserving cash as it awaits the next regulatory steps for its Lyme disease vaccine candida
- RTTNews · Mar 27, 9:42 AM EDTWeekly Buzz: CORT Wins FDA Nod In Cancer; MRK Acquires TERN; INSM Meets Trial Goals But VALN Misses(RTTNews) – This week's biotech landscape witnessed regulatory approvals across the U.S. and Japan, EU withdrawals, mergers, and clinical trial data readouts spanning lung disease, Lyme disease, kidney disease, ovarian cancer and Type 1 Diabetes.
- Zacks · Mar 24, 12:12 PM EDTVALN Stock Nosedives on Mixed Results From Lyme Disease Vaccine StudyValneva plunges 37% as Lyme vaccine study shows 70%+ efficacy but misses key statistical target, raising concerns despite plans for regulatory filings.
- RTTNews · Mar 23, 9:22 AM EDTValneva Plunges As Lyme Vaccine Misses Key Goal In Phase 3 Trial; Shows More Than 70% Efficacy(RTTNews) – Valneva SE (VALN) saw its stock drop sharply, even as the company and partner Pfizer announced that their Lyme disease vaccine candidate demonstrated more than 70% efficacy in a large Phase 3 study.
- RTTNews · Mar 23, 7:46 AM EDTPfizer: Lyme Disease Vaccine Candidate Shows Strong Efficacy In Phase 3 VALOR Trial(RTTNews) – Pfizer (PFE) and Valneva SE (VALN) announced topline results from the Phase 3 VALOR Vaccine Against Lyme for Outdoor Recreationists trial of its investigational 6-valent OspA-based Lyme disease vaccine candidate PF-07307405 demonstrating: in the pre-specified analyses
- RTTNews · Mar 18, 4:36 AM EDTValneva Reports Audited FY25 Results Ahead Of Full Presentation Later Today(RTTNews) – Valneva SE (VALN), a specialty vaccine company, reported its audited consolidated financial results for the full-year 2025, reaffirming its revenue performance and strengthened cash position as it prepares for a potentially pivotal year driven by its late-stage Lyme d
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Valneva SE from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.